首页> The journal of allergy and clinical immunology. Global> Tolerability and outcomes with rollout of tixagevimab-cilgavimab in patients with common variable immunodeficiency.

Tolerability and outcomes with rollout of tixagevimab-cilgavimab in patients with common variable immunodeficiency.

导出 LinkOut

翻译打印收藏纠错

第一作者： Daniela,Dluzynski

第一单位： Penn State College of Medicine, Hershey, Pa.

作者： Daniela,Dluzynski ^[1] ; Taha,Al-Shaikhly ^[2] ; Catharine I,Paules ^[3] ; Maria Paula,Henao ^[2]

作者单位： Penn State College of Medicine, Hershey, Pa. ^[1] Section of Asthma, Allergy, and Immunology, Penn State College of Medicine, Hershey, Pa. ^[2] Section of Infectious Disease, Penn State College of Medicine, Hershey, Pa. ^[3]

关键词 COVID-19 SARS-CoV-2 Tixagevimab-cilgavimab (Evusheld)common variable immunodeficiency mAb primary immunodeficiency

DOI 10.1016/j.jacig.2024.100293

PMID 39071730

发布时间 2024-07-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The journal of allergy and clinical immunology. Global

2024年3卷3期

100293页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

The journal of allergy and clinical immunology. Global

2024年3卷3期

100293页

检索历史清除

Tolerability and outcomes with rollout of tixagevimab-cilgavimab in patients with common variable immunodeficiency.

The journal of allergy and clinical immunology. Global

相似文献

同项目论文

The journal of allergy and clinical immunology. Global

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Tolerability and outcomes with rollout of tixagevimab-cilgavimab in patients with common variable immunodeficiency.

The journal of allergy and clinical immunology. Global

相似文献

同项目论文

The journal of allergy and clinical immunology. Global

相关期刊

检索历史清除